Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck
Learn about Rhythm Pharmaceuticals' FDA-approved drug IMCIVREE for obesity, including its potential expansion to children and ...
CNET3h
Eligible for Social Security Disability Insurance? Here's How to Apply
You can apply for Social Security Disability Insurance online, over the phone at 1-800-772-1213, or by stopping by a local ...
An appeals court has revived a challenge to President Biden’s Medicare drug price reduction program
A constitutional challenge to the Biden administration program enabling Medicare to negotiate lower prices for prescription ...
Zacks.com on MSN3d
Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 7.4% Jump Turn into More Strength?
Rhythm Pharmaceuticals, Inc. (RYTM) shares soared 7.4% in the last trading session to close at $53.17. The move was backed by solid volume with far more shares changing hands than in a normal session.
FierceBiotech4d
FDA scraps adcomm for Applied's rare disease drug ahead of November decision
After pushing back the decision date for Applied Therapeutics’ metabolic disorder drug govorestat, the FDA has now decided ...
Team publishes results from clinical trial evaluating cabozantinib in advanced neuroendocrine tumors
The Alliance for Clinical Trials in Oncology today announced that final results will be presented at ESMO 2024 from CABINET ...
Exelixis unveils additional data on Cabometyx for neuroendocrine tumors
Exelixis releases positive phase 3 data on Cabometyx for pancreatic and extra-pancreatic neuroendocrine tumors, seeking ...
Health.com5d
Turmeric, Ashwagandha, and 4 Other Herbal Supplements That Could Be Damaging Your Liver
The study, published last month in JAMA Network Open, found that the U.S. is seeing an uptick in drug-induced liver injury ...
Medexus Provides Update on Treosulfan NDA Review Process and Extended PDUFA Goal Date
Medexus Pharmaceuticals Inc. Toronto, Ontario and Chicago, Illinois–(Newsfile Corp. – September 16, 2024) – Medexus ...
Business Wire7d
Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic ...
Exelixis intends to submit a supplemental New Drug Application with the U.S. Food and Drug Administration for cabozantinib in combination with atezolizumab for mCRPC later this year. About CONTACT-02 ...
Business Wire8d
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC ...
Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today a ...